Literature DB >> 18214058

RNA expression of cytochrome P450 in breast cancer patients.

Radka Vaclavikova1, Miluse Hubackova, Jana Stribrna-Sarmanova, Roman Kodet, Marcela Mrhalova, Jan Novotny, Ivan Gut, Pavel Soucek.   

Abstract

BACKGROUND: The expression pattern of cytochrome P450 genes (CYPs) affected by tumorigenesis may have an important role in the progression of cancer and in the metabolism of anticancer drugs. The aim of the study was to determine the expression patterns of four cytochrome P450 genes (CYP1B1, 2C9, 2E1 and 3A4) in breast cancer patients. PATIENTS AND METHODS: mRNA expression was quantified by real-time PCR. Analyses of 40 sets of human breast tumors, adjacent non-tumor tissues and of 18 peripheral blood lymphocyte samples were performed. Expression levels were tested for correlation with clinical and pathological data of patients.
RESULTS: Expression levels of CYP2C9 and CYP3A4 were negligible. CYP1B1 expression was on average 50-fold higher than that of CYP2E1 with overexpression detected in one third of the tumors. Correlation of CYP1B1 expression in lymphocytes with that in non-tumor tissues was found. Significantly higher CYP2E1 expression was associated with an invasive lobular type of tumor, locally advanced disease as well as with non-tumor tissue of progesterone receptor-negative patients.
CONCLUSION: CYP2E1 expression has a potential role as a breast cancer prognosis marker. The observed high CYP1B1 expression in tumor cells may evoke changes in their response to drugs which are substrates of P450 1B1 and influence metabolism or activation of environmental carcinogens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18214058

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

Review 1.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

Review 2.  Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1.

Authors:  P S S Rao; Narasimha M Midde; Duane D Miller; Subhash Chauhan; Anil Kumar; Santosh Kumar
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

Review 3.  Involvement of cytochrome P450 enzymes in inflammation and cancer: a review.

Authors:  Maria Carolina Stipp; Alexandra Acco
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-28       Impact factor: 3.333

4.  Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN.

Authors:  Kaja S Borge; Silje Nord; Peter Van Loo; Ole C Lingjærde; Gjermund Gunnes; Grethe I G Alnæs; Hiroko K Solvang; Torben Lüders; Vessela N Kristensen; Anne-Lise Børresen-Dale; Frode Lingaas
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

5.  Cytochrome P450 2E1 (CYP2E1) regulates the response to oxidative stress and migration of breast cancer cells.

Authors:  Travis Leung; Ramkumar Rajendran; Subir Singh; Richa Garva; Marija Krstic-Demonacos; Constantinos Demonacos
Journal:  Breast Cancer Res       Date:  2013-11-08       Impact factor: 6.466

6.  Characteristic gene expression profiles in the progression from liver cirrhosis to carcinoma induced by diethylnitrosamine in a rat model.

Authors:  Yue-Fang Liu; Bin-Shan Zha; Hui-Lin Zhang; Xiao-Jing Zhu; Yu-Hua Li; Jin Zhu; Xiao-Hong Guan; Zhen-Qing Feng; Jian-Ping Zhang
Journal:  J Exp Clin Cancer Res       Date:  2009-07-29

Review 7.  Cytochrome P450: Implications for human breast cancer.

Authors:  Bin Luo; Dandan Yan; Honglin Yan; Jingping Yuan
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

Review 8.  Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies.

Authors:  Smarakan Sneha; Simon C Baker; Andrew Green; Sarah Storr; Radhika Aiyappa; Stewart Martin; Klaus Pors
Journal:  Biomedicines       Date:  2021-03-12

9.  Roadmap to personalized medicine.

Authors:  Malak Qattan; Constantinos Demonacos; Marija Krstic-Demonacos
Journal:  Croat Med J       Date:  2012-08       Impact factor: 1.351

10.  Functional PstI/RsaI polymorphism in CYP2E1 is associated with the development, progression and poor outcome of gastric cancer.

Authors:  Jin Feng; Xiaolin Pan; Junbo Yu; Zheng Chen; Hao Xu; Wael El-Rifai; Guoxin Zhang; Zekuan Xu
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.